Paris-based medtech developing Colovac, an endoluminal bypass to avoid temporary stomas in colorectal surgery.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series C SafeHeal extended its Series C by €10 million led by Asabys Partners, bringing total funding to €97.5 million, for the US trials of Colovac. | $11.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.